BioSpace News Archive

Takeda announced that the U.S. Food and Drug Administration has approved ADZYNMA for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura.

The U.S. behavioral health market size reached USD 83,470 million in 2022 and is estimated to surpass around USD 1,36,600 million by 2032, exhibiting an impressive CAGR of 5.1% between 2023 to 2032.

TRACON Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2023.

Aprea Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2023, and provided a business update.

IN8bio, Inc., a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent pipeline and business progress.

Hyperfine, Inc., the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system— announced third quarter 2023 financial results and provided a business update.

Vor Bio, a clinical-stage cell and genome engineering company, presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia.

Lyell Immunopharma, Inc. (Nasdaq: LYEL) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845, an investigational tumor infiltrating lymphocyte (TIL) product candidate for the treatment of patients with stage IIB-IV melanoma.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for the three months and nine months ended September 30, 2023, and provided a corporate update.